SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Exelixis’ presentation at the Barclays Capital 2011 Global Healthcare Conference will take place at 4:15 p.m. EDT/1:15 p.m. PDT on Tuesday, March 15, 2011, in Miami, Florida. The company was previously scheduled to present later in the day.
During the presentation, Michael Morrissey, Ph.D., the company’s president and chief executive officer, will review the most recent publicly available clinical data for cabozantinib (XL184) in castration-resistant prostate cancer (CRPC) and discuss the pivotal trial plans and regulatory strategy for the compound in CRPC. He will also discuss the company’s financial outlook and provide a general business update.
This event will be webcast and may be accessed on the Event Calendar page under Investors at www.exelixis.com.
Exelixis, Inc. is a biotechnology company committed to developing small molecule therapeutics for the treatment of cancer. Exelixis is focusing its resources and development efforts exclusively on cabozantinib, its most advanced solely-owned product candidate, in order to maximize the therapeutic and commercial potential of this compound. Exelixis believes cabozantinib has the potential to be a high-quality, differentiated pharmaceutical product that can make a meaningful difference in the lives of patients. Exelixis has also established a portfolio of other novel compounds that it believes have the potential to address serious unmet medical needs. For more information, please visit the company's web site at www.exelixis.com.
Charles Butler, 650-837-7277
Vice President, Investor Relations and Corporate Communications
KEYWORDS: United States North America California Florida
INDUSTRY KEYWORDS: Health Biotechnology Clinical Trials Oncology Pharmaceutical Professional Services Finance Research Science